Bibliographic Details
| Title: |
Multiple sclerosis, rituximab, and COVID‐19. |
| Authors: |
Langer‐Gould, Annette, Smith, Jessica B., Li, Bonnie H., Beaber, Brandon E, Brara, Sonu M, Debacker, Julie, Nielsen, Allen Scott, Amirova, Samira, Ayeni, Oluwasheyi |
| Source: |
Annals of Clinical & Translational Neurology; Apr2021, Vol. 8 Issue 4, p938-943, 6p |
| Subject Terms: |
COVID-19, MULTIPLE sclerosis, RITUXIMAB |
| Geographic Terms: |
SOUTHERN California |
| Company/Entity: |
KAISER Permanente (Company) |
| Abstract: |
We conducted a retrospective cohort study in Kaiser Permanente Southern California from 1 January 2020 to 30 September 2020. We found that rituximab‐treated persons with multiple sclerosis (pwMS, n = 1895) were more likely be hospitalized (n = 8, 33.3%), but not die (n = 0) from COVID‐19, compared to the 4.81 million non‐MS population (5.8% and 1.4%, respectively). Time in months (adjusted OR = 0.32, 95% CI = 0.15–0.69, p = 0.0033) and receiving 1000 mg compared to lower doses at last infusion (adjusted OR = 6.28, 95% CI = 1.38–28.5, p = 0.0173) were independent predictors of COVID‐19 severity. Rituximab‐treated pwMS should be counseled to take extra precautions in the 5 months following each infusion. Using extended dosing intervals and lower doses could be considered. [ABSTRACT FROM AUTHOR] |
|
Copyright of Annals of Clinical & Translational Neurology is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Complementary Index |
